, ,
04/29/2022
04/30/2022
Diabetes Update 2022
About
Agenda
Apr 29
ON-DEMAND: Accredited Symposium: The Role of Dual GIP/GLP-1 Receptor Agonism in Type 2 Diabetes
ON-DEMAND: Accredited Symposium: The Role of Dual GIP/GLP-1 Receptor Agonism in Type 2 Diabetes
Complete the evaluation form HERE
Learning Objectives:
-Describe the physiology of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1)
-Summarize the efficacy of dual GIP/GLP-1 receptor agonist therapy
-Discuss the safety and practical application of dual GIP/GLP-1 receptor agonist therapy
Learning Objectives:
-Describe the physiology of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1)
-Summarize the efficacy of dual GIP/GLP-1 receptor agonist therapy
-Discuss the safety and practical application of dual GIP/GLP-1 receptor agonist therapy
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated). This program was co-developed and planned with CSEM, the CPD Network and Eli Lilly to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity. This program is made possible through a grant from Lilly Inc.
Complete the evaluation form HERE
Learning Objectives:
-Describe the physiology of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1)
-Summarize the efficacy of dual GIP/GLP-1 receptor agonist therapy
-Discuss the safety and practical application of dual GIP/GLP-1 receptor agonist therapy
Learning Objectives:
-Describe the physiology of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1)
-Summarize the efficacy of dual GIP/GLP-1 receptor agonist therapy
-Discuss the safety and practical application of dual GIP/GLP-1 receptor agonist therapy
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated). This program was co-developed and planned with CSEM, the CPD Network and Eli Lilly to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity. This program is made possible through a grant from Lilly Inc.
Start
9:00 AM
End
10:00 AM
ON-DEMAND: Welcome and Introductions | Diabetes and Heart Failure: What must a diabetologist know? - Shelley Zieroth, MD | Obesity and Diabetes - Sean Wharton, MD | Decolonizing Diabetes Health Care - Randal Bell | Session Moderator: Zaina Albalawi, MD
ON-DEMAND: Welcome and Introductions | Diabetes and Heart Failure: What must a diabetologist know? - Shelley Zieroth, MD | Obesity and Diabetes - Sean Wharton, MD | Decolonizing Diabetes Health Care - Randal Bell | Session Moderator: Zaina Albalawi, MD
Welcome and Introductions - Zaina Albalawi, MD
Diabetes and Heart Failure: What must a diabetologist know? - Shelley Zieroth, MD
Obesity and Diabetes - Sean Wharton, MD
Decolonizing Diabetes Health Care - Randal Bell
Welcome and Introductions - Zaina Albalawi, MD
Diabetes and Heart Failure: What must a diabetologist know? - Shelley Zieroth, MD
Obesity and Diabetes - Sean Wharton, MD
Decolonizing Diabetes Health Care - Randal Bell
Start
10:00 AM
End
11:35 AM
ON-DEMAND: Corridor Consult: Early Initiation of GLP1-RAs: A case-based discussion - Navreet Deol, MD & David Kennedy, MD (non-accredited)
ON-DEMAND: Corridor Consult: Early Initiation of GLP1-RAs: A case-based discussion - Navreet Deol, MD & David Kennedy, MD (non-accredited)
Join Dr. Navreet Deol and Dr. David Kennedy for conversation on the benefits of early initiation of GLP1-RAs in patients with diabetes and CV risk. What do the guidelines tell us about when to start, and how can we ensure that we are achieving optimal cardiorenal protection?
This program is sponsored by Novo Nordisk Canada
This program is sponsored by Novo Nordisk Canada
Join Dr. Navreet Deol and Dr. David Kennedy for conversation on the benefits of early initiation of GLP1-RAs in patients with diabetes and CV risk. What do the guidelines tell us about when to start, and how can we ensure that we are achieving optimal cardiorenal protection?
This program is sponsored by Novo Nordisk Canada
This program is sponsored by Novo Nordisk Canada
Start
11:35 AM
End
11:55 AM
ON-DEMAND: Accredited Symposium: Does My Patient With Shortness of Breath have HFpEF?
ON-DEMAND: Accredited Symposium: Does My Patient With Shortness of Breath have HFpEF?
Complete the evaluation form HERE
Learning objectives
Learning objectives
- Recognize the prevalence of heart failure with preserved ejection fraction as an endocrinologist and understand why it is important for endocrinologists to diagnose patients with HFpEF
- Understand the tests required to diagnose heart failure with preserved ejection fraction and exclude other conditions with similar presentations
- Describe current and emerging treatment pathways to optimize the management of patients with heart failure with preserved ejection fraction
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated). This program was co-developed and planned with CSEM, the CPD Network, Boehringer-Ingelheim and Eli-Lilly to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity.
This program is supported by an educational grant from Boehringer-Ingelheim and Eli-Lilly.
Complete the evaluation form HERE
Learning objectives
Learning objectives
- Recognize the prevalence of heart failure with preserved ejection fraction as an endocrinologist and understand why it is important for endocrinologists to diagnose patients with HFpEF
- Understand the tests required to diagnose heart failure with preserved ejection fraction and exclude other conditions with similar presentations
- Describe current and emerging treatment pathways to optimize the management of patients with heart failure with preserved ejection fraction
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated). This program was co-developed and planned with CSEM, the CPD Network, Boehringer-Ingelheim and Eli-Lilly to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity.
This program is supported by an educational grant from Boehringer-Ingelheim and Eli-Lilly.
Start
12:00 PM
End
1:00 PM
ON-DEMAND: Update on Incretin Therapies - Alice Y.Y. Cheng, MD | Nutrition and Diabetes - Michael Mindrum, MD | Session Moderator: Zaina Albalawi, MD
ON-DEMAND: Update on Incretin Therapies - Alice Y.Y. Cheng, MD | Nutrition and Diabetes - Michael Mindrum, MD | Session Moderator: Zaina Albalawi, MD
Start
1:05 PM
End
2:05 PM
ON-DEMAND: Corridor Consult : Q&A Session: Does my patient with shortness of breath have HFpEF? - Sara Stafford, MD & Kim Connelly, MD
ON-DEMAND: Corridor Consult : Q&A Session: Does my patient with shortness of breath have HFpEF? - Sara Stafford, MD & Kim Connelly, MD
In this session, Dr. Sara Stafford and Dr. Kim Connelly will discuss heart failure with preserved ejection fraction (HFpEF) and when endocrinologists might suspect it in their patients with diabetes. What should we be looking for, what tests can be considered, and what symptoms might suggest further investigation?
This program is sponsored by Boehringer Ingelheim and Eli Lilly
This program is sponsored by Boehringer Ingelheim and Eli Lilly
In this session, Dr. Sara Stafford and Dr. Kim Connelly will discuss heart failure with preserved ejection fraction (HFpEF) and when endocrinologists might suspect it in their patients with diabetes. What should we be looking for, what tests can be considered, and what symptoms might suggest further investigation?
This program is sponsored by Boehringer Ingelheim and Eli Lilly
This program is sponsored by Boehringer Ingelheim and Eli Lilly
Start
2:05 PM
End
2:30 PM
ON-DEMAND: Diabetes and Mental Health - Barry Simon, MD | Diabetes and Chronic Kidney Disease - David Cherney, MD | Session Moderator: Zaina Albalawi, MD
ON-DEMAND: Diabetes and Mental Health - Barry Simon, MD | Diabetes and Chronic Kidney Disease - David Cherney, MD | Session Moderator: Zaina Albalawi, MD
Start
2:30 PM
End
3:30 PM
ON-DEMAND: Accredited Symposium: Data Overload: Making Use of Continuous Glucose Data in Practice and Research
ON-DEMAND: Accredited Symposium: Data Overload: Making Use of Continuous Glucose Data in Practice and Research
Complete the evaluation form HERE
Learning objectives
- Describe the concept of Time in Range and how it can be applied in clinical research
- Utilize continuous glucose data to guide clinical decisions with patients with Type 1 and Type 2 diabetes
- Discuss results of a recent clinical trial utilizing CGM data as the primary outcome and its relevance to clinical practice
- Utilize continuous glucose data to guide clinical decisions with patients with Type 1 and Type 2 diabetes
- Discuss results of a recent clinical trial utilizing CGM data as the primary outcome and its relevance to clinical practice
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated). This program was co-developed and planned with CSEM, the CPD Network and Sanofi to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity.
This program is supported by an educational grant from Sanofi.
Complete the evaluation form HERE
Learning objectives
- Describe the concept of Time in Range and how it can be applied in clinical research
- Utilize continuous glucose data to guide clinical decisions with patients with Type 1 and Type 2 diabetes
- Discuss results of a recent clinical trial utilizing CGM data as the primary outcome and its relevance to clinical practice
- Utilize continuous glucose data to guide clinical decisions with patients with Type 1 and Type 2 diabetes
- Discuss results of a recent clinical trial utilizing CGM data as the primary outcome and its relevance to clinical practice
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated). This program was co-developed and planned with CSEM, the CPD Network and Sanofi to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity.
This program is supported by an educational grant from Sanofi.
Start
3:30 PM
End
4:30 PM
IN PERSON EXCLUSIVE Keynote Presentation: Digital Models of Diabetes Care - Athena Phillis-Tsimikas, MD
IN PERSON EXCLUSIVE Keynote Presentation: Digital Models of Diabetes Care - Athena Phillis-Tsimikas, MD
Start
4:30 PM
End
4:50 PM
PODCAST: Does IT make a difference? Peter Lin, MD & James Kim, MD
PODCAST: Does IT make a difference? Peter Lin, MD & James Kim, MD
On this episode of the Diabetes Update 2022 podcast series, we welcome Dr Peter Lin, a family physician, and Director of Primary Care Initiatives at the Canadian Heart Research Group. Also joining us is Dr James Kim, a general practitioner and steering committee member of the Diabetes Canada Clinical Practice Guideline.
A safe and proper insulin injection technique is globally recommended to improve blood glucose control. Sadly, most patients receive minimal training in injection techniques. In this episode, our guests discuss what patients need to know about effective and safe injection technique, the impact of needle size and angle of insertion, poor site rotation, advice regarding needles reuse, and resultant impact on patient HbA1c levels. Although the drug is important, the proper delivery of the drug is equally important.
This program was made possible through funding from Becton Dickinson.
On this episode of the Diabetes Update 2022 podcast series, we welcome Dr Peter Lin, a family physician, and Director of Primary Care Initiatives at the Canadian Heart Research Group. Also joining us is Dr James Kim, a general practitioner and steering committee member of the Diabetes Canada Clinical Practice Guideline.
A safe and proper insulin injection technique is globally recommended to improve blood glucose control. Sadly, most patients receive minimal training in injection techniques. In this episode, our guests discuss what patients need to know about effective and safe injection technique, the impact of needle size and angle of insertion, poor site rotation, advice regarding needles reuse, and resultant impact on patient HbA1c levels. Although the drug is important, the proper delivery of the drug is equally important.
This program was made possible through funding from Becton Dickinson.
Start
4:50 PM
End
5:00 PM
PODCAST: Early Initiation of GLP-1RAs - Akshay Jain, MD & Sonja Reichert, MD
PODCAST: Early Initiation of GLP-1RAs - Akshay Jain, MD & Sonja Reichert, MD
In this new Diabetes Update 2022 podcast topic ‘Early Initiation of GLP-1RAs in the Continuum of Care’, we are joined by Dr Akshay Jain, an endocrinologist and President of the Canadian Chapter of the American Association of Clinical Endocrinologists, and Dr Sonja Reichert, Associate Professor, Department of Family Medicine at the Schulich Centre for Studies in Family Medicine, Western University.
Through a patient case study, our guests discuss the benefits beyond glucose lowering for GLP1-RAs in patients with diabetes, including CV risk reduction and weight management, as well as the benefits of early initation. Also covered in this episode are practical prescribing tips and how to manage side effects or patient concerns with injectables.
Through a patient case study, our guests discuss the benefits beyond glucose lowering for GLP1-RAs in patients with diabetes, including CV risk reduction and weight management, as well as the benefits of early initation. Also covered in this episode are practical prescribing tips and how to manage side effects or patient concerns with injectables.
The information and opinions expressed in this podcast are solely those of the individuals involved and do not represent those of Novo Nordisk. This podcast does not constitute medical advise and is only meant to educate and inform the listener. This podcast has been supported by educational funding from Novo Nordisk.
In this new Diabetes Update 2022 podcast topic ‘Early Initiation of GLP-1RAs in the Continuum of Care’, we are joined by Dr Akshay Jain, an endocrinologist and President of the Canadian Chapter of the American Association of Clinical Endocrinologists, and Dr Sonja Reichert, Associate Professor, Department of Family Medicine at the Schulich Centre for Studies in Family Medicine, Western University.
Through a patient case study, our guests discuss the benefits beyond glucose lowering for GLP1-RAs in patients with diabetes, including CV risk reduction and weight management, as well as the benefits of early initation. Also covered in this episode are practical prescribing tips and how to manage side effects or patient concerns with injectables.
Through a patient case study, our guests discuss the benefits beyond glucose lowering for GLP1-RAs in patients with diabetes, including CV risk reduction and weight management, as well as the benefits of early initation. Also covered in this episode are practical prescribing tips and how to manage side effects or patient concerns with injectables.
The information and opinions expressed in this podcast are solely those of the individuals involved and do not represent those of Novo Nordisk. This podcast does not constitute medical advise and is only meant to educate and inform the listener. This podcast has been supported by educational funding from Novo Nordisk.
Start
4:50 PM
End
5:00 PM
PODCAST: Exploring Treatment Strategies for Diabetic Kidney Disease - Stavroula Christopoulos, MD & Normand Proulx, MD
PODCAST: Exploring Treatment Strategies for Diabetic Kidney Disease - Stavroula Christopoulos, MD & Normand Proulx, MD
In this episode of the Diabetes Update 2022 podcast series, we are pleased to welcome Dr Stavroula Christopoulos, endocrinologist and assistant professor at McGill University’s department of Medicine, and Dr Normand Proulx who is a physician specializing in Nephrology.
What is cardiorenal syndrome and how common is it in everyday practice? Using a case presentation, our guests discuss practical strategies for improving quality of life while protecting the heart and kidneys, along with evidence and recommendations for adding an SGLT2i in these patients and how to initiate them. As well, what other considerations need to be taken with regards to A1C, eGFR and concomitant use with other medications?
This program was made possible through funding from Janssen.
In this episode of the Diabetes Update 2022 podcast series, we are pleased to welcome Dr Stavroula Christopoulos, endocrinologist and assistant professor at McGill University’s department of Medicine, and Dr Normand Proulx who is a physician specializing in Nephrology.
What is cardiorenal syndrome and how common is it in everyday practice? Using a case presentation, our guests discuss practical strategies for improving quality of life while protecting the heart and kidneys, along with evidence and recommendations for adding an SGLT2i in these patients and how to initiate them. As well, what other considerations need to be taken with regards to A1C, eGFR and concomitant use with other medications?
This program was made possible through funding from Janssen.
Start
4:50 PM
End
4:50 PM
PODCAST: Incorporating Novel Cardiovascular (CV) Risk Reduction Strategies for Diabetes Patients: Where Icosapent Ethyl (IPE) Fits into Our Practice - Jeremy Gilbert, MD & Peter Lin, MD
PODCAST: Incorporating Novel Cardiovascular (CV) Risk Reduction Strategies for Diabetes Patients: Where Icosapent Ethyl (IPE) Fits into Our Practice - Jeremy Gilbert, MD & Peter Lin, MD
On this episode of Diabetes Update 2022 podcast series titled, ‘Incorporating novel cardiovascular (CV) risk reduction strategies for diabetes patients: where icosapent ethyl (IPE) fits into our practice’, we welcome Dr Peter Lin, a family physician and Director of Primary Care Initiatives at the Canadian Heart Research Group. He is joined by Dr Jeremy Gilbert, who is an endocrinologist and associate professor at the Sunnybrook Health Sciences Centre.
In this episode, our guests discuss the concurrent triglyceride lowering management alongside LDL lowering management in high-risk patients with cardiovascular disease, as outlined in the 2021 Canadian Dyslipidemia guidelines, and the incremental benefits reported at the REDUCE-IT trial for icosapent ethyl (IPE), the first non-LDL focused lipid therapy, as an adjunct therapy. Identifying candidate patients for IPE, and the role of multiple healthcare providers in patient management are topics covered in this program.
This program was made possible through funding from HLS Therapeutics.
On this episode of Diabetes Update 2022 podcast series titled, ‘Incorporating novel cardiovascular (CV) risk reduction strategies for diabetes patients: where icosapent ethyl (IPE) fits into our practice’, we welcome Dr Peter Lin, a family physician and Director of Primary Care Initiatives at the Canadian Heart Research Group. He is joined by Dr Jeremy Gilbert, who is an endocrinologist and associate professor at the Sunnybrook Health Sciences Centre.
In this episode, our guests discuss the concurrent triglyceride lowering management alongside LDL lowering management in high-risk patients with cardiovascular disease, as outlined in the 2021 Canadian Dyslipidemia guidelines, and the incremental benefits reported at the REDUCE-IT trial for icosapent ethyl (IPE), the first non-LDL focused lipid therapy, as an adjunct therapy. Identifying candidate patients for IPE, and the role of multiple healthcare providers in patient management are topics covered in this program.
This program was made possible through funding from HLS Therapeutics.
Start
4:50 PM
End
5:00 PM
PODCAST: Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology - Alice Cheng, MD & Anil Gupta, MD
PODCAST: Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology - Alice Cheng, MD & Anil Gupta, MD
On this episode of the Diabetes Update 2022 podcast series titled ‘Let’s Be Friends: a collaborative conversation between endocrinology and cardiology’, we are pleased to welcome Dr. Alice Cheng, an endocrinologist, and Associate Professor in the Department of Medicine at the University of Toronto. She is accompanied by Dr Anil Gupta, cardiologist and medical director at the CCU and Clinical Cardiology Trillium Health partner. He is also a partner at the Mississauga Clinical Research Centre.
In this conversation, our guests discuss the different perspectives and considerations endocrinologists and cardiologists have when starting on antihyperglycemic therapy. How do cardiology and endocrinology work together? Where do the lines blur with shared patient care and how can we better communicate with each other to improve patient outcomes?
This program was made possible through funding from Boehringer-Ingelheim and Eli Lilly
On this episode of the Diabetes Update 2022 podcast series titled ‘Let’s Be Friends: a collaborative conversation between endocrinology and cardiology’, we are pleased to welcome Dr. Alice Cheng, an endocrinologist, and Associate Professor in the Department of Medicine at the University of Toronto. She is accompanied by Dr Anil Gupta, cardiologist and medical director at the CCU and Clinical Cardiology Trillium Health partner. He is also a partner at the Mississauga Clinical Research Centre.
In this conversation, our guests discuss the different perspectives and considerations endocrinologists and cardiologists have when starting on antihyperglycemic therapy. How do cardiology and endocrinology work together? Where do the lines blur with shared patient care and how can we better communicate with each other to improve patient outcomes?
This program was made possible through funding from Boehringer-Ingelheim and Eli Lilly
Start
4:50 PM
End
5:00 PM
PODCAST: Management of Type I Diabetes in Pregnancy - Amish Parikh, MD & Pt. Kristen McLellan
PODCAST: Management of Type I Diabetes in Pregnancy - Amish Parikh, MD & Pt. Kristen McLellan
In this new Diabetes Update 2022 podcast topic ‘Management of Type I Diabetes in Pregnancy’, we are joined by Dr Amish Parikh who is a staff internist and endocrinologist at Trillium Health Partners, Ontario with his patient Kristen McLellan.
In this podcast, Dr Parikh and Kristen review her experience of using insulin pump therapy as a method to manage Type I diabetes optimally throughout her three pregnancies. Dr Parikh discusses the role of preconception care and counselling, benefits of insulin pumps, and the advantages of virtual care monitoring with the diabetes team, allowing smooth adjustment during various phases of both pregnancy and postpartum stages.
This podcast has been supported by educational funding from Insulet.
In this podcast, Dr Parikh and Kristen review her experience of using insulin pump therapy as a method to manage Type I diabetes optimally throughout her three pregnancies. Dr Parikh discusses the role of preconception care and counselling, benefits of insulin pumps, and the advantages of virtual care monitoring with the diabetes team, allowing smooth adjustment during various phases of both pregnancy and postpartum stages.
This podcast has been supported by educational funding from Insulet.
In this new Diabetes Update 2022 podcast topic ‘Management of Type I Diabetes in Pregnancy’, we are joined by Dr Amish Parikh who is a staff internist and endocrinologist at Trillium Health Partners, Ontario with his patient Kristen McLellan.
In this podcast, Dr Parikh and Kristen review her experience of using insulin pump therapy as a method to manage Type I diabetes optimally throughout her three pregnancies. Dr Parikh discusses the role of preconception care and counselling, benefits of insulin pumps, and the advantages of virtual care monitoring with the diabetes team, allowing smooth adjustment during various phases of both pregnancy and postpartum stages.
This podcast has been supported by educational funding from Insulet.
In this podcast, Dr Parikh and Kristen review her experience of using insulin pump therapy as a method to manage Type I diabetes optimally throughout her three pregnancies. Dr Parikh discusses the role of preconception care and counselling, benefits of insulin pumps, and the advantages of virtual care monitoring with the diabetes team, allowing smooth adjustment during various phases of both pregnancy and postpartum stages.
This podcast has been supported by educational funding from Insulet.
Start
4:50 PM
End
5:00 PM
PODCAST: Stroke in Diabetes - Ron Goldenberg, MD & Tess Fitzpatrick, MD
PODCAST: Stroke in Diabetes - Ron Goldenberg, MD & Tess Fitzpatrick, MD
On this episode of the Diabetes Update 2022 podcast series titled ‘Stroke in Diabetes’, we are pleased to welcome Dr. Ron Goldenberg, consultant endocrinologist affiliated with North York General Hospital in Toronto, and LMC Diabetes and Endocrinology in Thornhill. We also welcome Dr Tess Fitzpatrick, a stroke neurologist, and a clinical stroke fellow at Sunnybrook Health Sciences Centre in Toronto.
In this conversation, our guests discuss the pathophysiology and contributing factors leading up to stroke in patients with diabetes, as well as the Canadian Stroke Best Practice Guidelines for early screening, recognition, management, and prevention of stroke. Additionally, the episode discusses the importance of a comprehensive management approach to diabetes stroke prevention, including A1C control, cholesterol management, lifestyle modifications, and the role of GLP-1 RAs with proven stroke reduction benefit independent of patients' baseline A1C levels in managing multi-morbid cases.
This program was made possible through funding from Lilly.
On this episode of the Diabetes Update 2022 podcast series titled ‘Stroke in Diabetes’, we are pleased to welcome Dr. Ron Goldenberg, consultant endocrinologist affiliated with North York General Hospital in Toronto, and LMC Diabetes and Endocrinology in Thornhill. We also welcome Dr Tess Fitzpatrick, a stroke neurologist, and a clinical stroke fellow at Sunnybrook Health Sciences Centre in Toronto.
In this conversation, our guests discuss the pathophysiology and contributing factors leading up to stroke in patients with diabetes, as well as the Canadian Stroke Best Practice Guidelines for early screening, recognition, management, and prevention of stroke. Additionally, the episode discusses the importance of a comprehensive management approach to diabetes stroke prevention, including A1C control, cholesterol management, lifestyle modifications, and the role of GLP-1 RAs with proven stroke reduction benefit independent of patients' baseline A1C levels in managing multi-morbid cases.
This program was made possible through funding from Lilly.
Start
4:50 PM
End
5:00 PM
PODCAST: What Are We Missing in Patients with CKD and T2D? - Alice Cheng, MD & Phil McFarlane, MD
PODCAST: What Are We Missing in Patients with CKD and T2D? - Alice Cheng, MD & Phil McFarlane, MD
On this episode of the Diabetes Update 2022 podcast series titled ‘What are we missing in patients with CKD and T2D?’, we are pleased to welcome Dr. Alice Cheng, an endocrinologist, and Associate Professor in the Department of Medicine at the University of Toronto. She is accompanied by Dr Phil McFarlane, clinical investigator in the Division of Nephrology at St. Michael’s Hospital in Toronto, and an Assistant Professor at the University of Toronto.
In this conversation, our guests discuss what is meant by chronic kidney disease in diabetes, diagnostic methods, and the four pillars of CKD management indicated by the Diabetes Canada Guidelines. The guests also explore the results and efficacy of Finerenone, a new class three generation aldosterone agonist in improving and preventing CKD outcomes in patients with a broad range of kidney function, considering the FIGARO and FIDELIO trials. Finally, the guests discuss the use of SGLT2is with or without finerenone, and potential additional cardiorenal protective benefits obtained from both drugs.
This program was made possible through funding from Bayer.On this episode of the Diabetes Update 2022 podcast series titled ‘What are we missing in patients with CKD and T2D?’, we are pleased to welcome Dr. Alice Cheng, an endocrinologist, and Associate Professor in the Department of Medicine at the University of Toronto. She is accompanied by Dr Phil McFarlane, clinical investigator in the Division of Nephrology at St. Michael’s Hospital in Toronto, and an Assistant Professor at the University of Toronto.
In this conversation, our guests discuss what is meant by chronic kidney disease in diabetes, diagnostic methods, and the four pillars of CKD management indicated by the Diabetes Canada Guidelines. The guests also explore the results and efficacy of Finerenone, a new class three generation aldosterone agonist in improving and preventing CKD outcomes in patients with a broad range of kidney function, considering the FIGARO and FIDELIO trials. Finally, the guests discuss the use of SGLT2is with or without finerenone, and potential additional cardiorenal protective benefits obtained from both drugs.
This program was made possible through funding from Bayer.Start
4:50 PM
End
4:05 PM
Apr 30
ON-DEMAND: Accredited Symposium: A Multidisciplinary Perspective on the Role of GLP-1RAs in Diabetes
ON-DEMAND: Accredited Symposium: A Multidisciplinary Perspective on the Role of GLP-1RAs in Diabetes
Complete the evaluation form HERE
Learning objectives
- Recognize the increased burden of CV Risk and CVD in patients with T2D, and identify those in whom guideline-based risk reduction would be beneficial
- Recognize the increased burden of CV Risk and CVD in patients with T2D, and identify those in whom guideline-based risk reduction would be beneficial
- Utilize clinical practice guidelines to understand the role of GLP-1 RAs and the benefits of early initiation in patients with T2D and CV risk
- Review the practical patient management considerations of GLP-1RAs such as dosing, side effects, use in special populations, and the impact on other comorbidities
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated). This program was co-developed and planned with CSEM, the CPD Network and Novo Nordisk to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity.
This program is supported by an educational grant from Novo Nordisk Canada Inc.
Complete the evaluation form HERE
Learning objectives
- Recognize the increased burden of CV Risk and CVD in patients with T2D, and identify those in whom guideline-based risk reduction would be beneficial
- Recognize the increased burden of CV Risk and CVD in patients with T2D, and identify those in whom guideline-based risk reduction would be beneficial
- Utilize clinical practice guidelines to understand the role of GLP-1 RAs and the benefits of early initiation in patients with T2D and CV risk
- Review the practical patient management considerations of GLP-1RAs such as dosing, side effects, use in special populations, and the impact on other comorbidities
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated). This program was co-developed and planned with CSEM, the CPD Network and Novo Nordisk to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity.
This program is supported by an educational grant from Novo Nordisk Canada Inc.
Start
9:00 AM
End
10:00 AM
ON-DEMAND: Welcome and Introductions | Fatty Liver Disease and NASH - Giada Sebastiani, MD | Technology Update - Alanna Weisman, MD | Exercise and Type 1 Diabetes - Jane Yardley, PhD | Session Moderator: Zaina Albalawi, MD
ON-DEMAND: Welcome and Introductions | Fatty Liver Disease and NASH - Giada Sebastiani, MD | Technology Update - Alanna Weisman, MD | Exercise and Type 1 Diabetes - Jane Yardley, PhD | Session Moderator: Zaina Albalawi, MD
Welcome and Introductions - Zaina Albalawi, MD
Fatty Liver Disease and NASH - Giada Sebastiani, MD
Technology Update - Alanna Weisman, MD
Exercise and Type 1 Diabetes - Jane Yardley, PhD
Panel Discussion and Q&A - Giada Sebastiani, MD; Alanna Weisman, MD; Jane Yardley, PhD
Welcome and Introductions - Zaina Albalawi, MD
Fatty Liver Disease and NASH - Giada Sebastiani, MD
Technology Update - Alanna Weisman, MD
Exercise and Type 1 Diabetes - Jane Yardley, PhD
Panel Discussion and Q&A - Giada Sebastiani, MD; Alanna Weisman, MD; Jane Yardley, PhD
Start
10:00 AM
End
11:35 AM
ON-DEMAND: Corridor Consult: Let's Be Friends: A collaborative conversation between Endocrinology and Cardiology - Alice Y.Y. Cheng, MD & Anil Gupta, MD (non-accredited)
ON-DEMAND: Corridor Consult: Let's Be Friends: A collaborative conversation between Endocrinology and Cardiology - Alice Y.Y. Cheng, MD & Anil Gupta, MD (non-accredited)
A colleague calls you to discuss a complex case. What advice do you offer for management while in the hospital? Upon discharge? Is a formal consult needed? How can cardiologists and endocrinologists best work together to optimize outcomes in our patients? Join us for this collaborative conversation and interact live with Dr. Cheng and Dr. Gupta!
This program is sponsored by Boehringer Ingelheim and Eli Lilly
This program is sponsored by Boehringer Ingelheim and Eli Lilly
A colleague calls you to discuss a complex case. What advice do you offer for management while in the hospital? Upon discharge? Is a formal consult needed? How can cardiologists and endocrinologists best work together to optimize outcomes in our patients? Join us for this collaborative conversation and interact live with Dr. Cheng and Dr. Gupta!
This program is sponsored by Boehringer Ingelheim and Eli Lilly
This program is sponsored by Boehringer Ingelheim and Eli Lilly
Start
11:35 AM
End
11:55 AM
ON-DEMAND: Accredited Symposium: Obesity Management in Your Practice: Simple Recommendations to Improve Patient Care - Obesity Pharmacotherapy
ON-DEMAND: Accredited Symposium: Obesity Management in Your Practice: Simple Recommendations to Improve Patient Care - Obesity Pharmacotherapy
Complete the evaluation form HERE
Learning objectives
Learning objectives
- Review the Obesity Canada clinical practice guidelines
- Apply the key principles of the guidelines to manage patients with obesity
- Discuss how clinicians can individualize obesity pharmacotherapy based on the needs of the patient with obesity
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated).
This program was co-developed and planned with CSEM, the Canadian Collaborative Research Network, and Novo Nordisk to achieve scientific integrity, objectivity, and balance.
This program was co-developed and planned with CSEM, the Canadian Collaborative Research Network, and Novo Nordisk to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity.
This program is supported by an educational grant from Novo Nordisk Canada Inc.
Complete the evaluation form HERE
Learning objectives
Learning objectives
- Review the Obesity Canada clinical practice guidelines
- Apply the key principles of the guidelines to manage patients with obesity
- Discuss how clinicians can individualize obesity pharmacotherapy based on the needs of the patient with obesity
This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism. You may claim a maximum of 1.0 hours (credits are automatically calculated).
This program was co-developed and planned with CSEM, the Canadian Collaborative Research Network, and Novo Nordisk to achieve scientific integrity, objectivity, and balance.
This program was co-developed and planned with CSEM, the Canadian Collaborative Research Network, and Novo Nordisk to achieve scientific integrity, objectivity, and balance.
Participants should only claim credits commensurate with the extent of their participation in the activity.
This program is supported by an educational grant from Novo Nordisk Canada Inc.
Start
12:00 PM
End
1:00 PM
ON-DEMAND: Update on Dyslipidemia - George Thanassoulis, MD | Remission in Type 2 Diabetes - Zubin Punthakee, MD | Session Moderator: Alanna Weisman, MD
ON-DEMAND: Update on Dyslipidemia - George Thanassoulis, MD | Remission in Type 2 Diabetes - Zubin Punthakee, MD | Session Moderator: Alanna Weisman, MD
Update on Dyslipidemia - George Thanassoulis, MD
Remission in Type 2 Diabetes - Zubin Punthakee, MD
Panel Discussion and Q&A - George Thanassoulis, MD & Zubin Punthakee, MD
Update on Dyslipidemia - George Thanassoulis, MD
Remission in Type 2 Diabetes - Zubin Punthakee, MD
Panel Discussion and Q&A - George Thanassoulis, MD & Zubin Punthakee, MD
Start
1:05 PM
End
2:05 PM
ON-DEMAND: Corridor Consult: Q&A Session: The Role of Dual GIP/GLP-1 Receptor Agonism in Type 2 Diabetes - Alice Y.Y. Cheng, MD & Richard Dumas, MD (non-accredited)
ON-DEMAND: Corridor Consult: Q&A Session: The Role of Dual GIP/GLP-1 Receptor Agonism in Type 2 Diabetes - Alice Y.Y. Cheng, MD & Richard Dumas, MD (non-accredited)
Join Dr. Alice Cheng and Dr. Richard Dumas in a conversation about the role of new therapies, specifically GIP/GLP1-RAs in diabetes management. Should we be reframing how we think about diabetes, what are meaningful outcomes for patients, and what considerations should be taken when selecting therapies for our patients?
This program is sponsored by Eli Lilly
This program is sponsored by Eli Lilly
Join Dr. Alice Cheng and Dr. Richard Dumas in a conversation about the role of new therapies, specifically GIP/GLP1-RAs in diabetes management. Should we be reframing how we think about diabetes, what are meaningful outcomes for patients, and what considerations should be taken when selecting therapies for our patients?
This program is sponsored by Eli Lilly
This program is sponsored by Eli Lilly
Start
2:05 PM
End
2:25 PM
ON-DEMAND: Current and Future Approaches to Type 1 Diabetes: Beyond Insulin and Technology - Peter Senior, MD | Debate: Use of SGLT2is in Hospital - Jacob A. Udell, MD and Shelley Zieroth, MD | Closing Remarks | Session Moderator: Zaina Albalawi, MD
ON-DEMAND: Current and Future Approaches to Type 1 Diabetes: Beyond Insulin and Technology - Peter Senior, MD | Debate: Use of SGLT2is in Hospital - Jacob A. Udell, MD and Shelley Zieroth, MD | Closing Remarks | Session Moderator: Zaina Albalawi, MD
Evaluation form for day 2: Click HERE
Current and Future Approaches to Type 1 Diabetes: Beyond Insulin and Technology - Peter Senior, MD
Current and Future Approaches to Type 1 Diabetes: Beyond Insulin and Technology - Peter Senior, MD
Debate: Use of SGLT2is in Hospital - Jacob A. Udell, MD & Shelley Zieroth, MD
Panel Discussion and Q&A - Peter Senior, MD; Jacob A. Udell, MD; Shelley Zieroth, MD
Closing Remarks - Zaina Albalawi, MD & Alanna Weisman, MD
Closing Remarks - Zaina Albalawi, MD & Alanna Weisman, MD
Evaluation form for day 2: Click HERE
Current and Future Approaches to Type 1 Diabetes: Beyond Insulin and Technology - Peter Senior, MD
Current and Future Approaches to Type 1 Diabetes: Beyond Insulin and Technology - Peter Senior, MD
Debate: Use of SGLT2is in Hospital - Jacob A. Udell, MD & Shelley Zieroth, MD
Panel Discussion and Q&A - Peter Senior, MD; Jacob A. Udell, MD; Shelley Zieroth, MD
Closing Remarks - Zaina Albalawi, MD & Alanna Weisman, MD
Closing Remarks - Zaina Albalawi, MD & Alanna Weisman, MD
Start
2:30 PM
End
4:00 PM
Speakers
Planning Committee Co-Chair
Alanna Weisman
Zaina Albalawi
Faculty
Athena Phillis-Tsimikas
Akshay Jain
@
Anil Gupta
Bruce Perkins
Dan Ngui
Julie Lovshin
Kim A. Connelly
Richard Dumas
Sandeep G. Aggarwal
Susie Jin
Alescia Azzola
MD, FRCPC Cert. Endo
Alice Y.Y. Cheng
Barry Simon
David Cherney
David Kennedy
George Thanassoulis
Giada Sebastiani
Jacob A. Udell
Jane Yardley
Jeffrey Habert
Jeremy Gilbert
MD, FRCPC
Megha Poddar
Michael Mindrum
Navreet Deol
Peter Senior
Randal Bell
Sara Stafford
Sean Wharton
Shelley Zieroth
Zubin Punthakee
Sponsors
Download app
